İsmail Beypınar, Hacer Demir, Şendağ Yaslıkaya, Tolga Köşeci, Bilgin Demir, Gökhan Çolak, Ahmet Burak Ağaoğlu, Mustafa Şahbazlar, Pervin Can Şancı, Devrim Çabuk, Ulaş Işık, Elif Şahin, Alper Coşkun, Burcu Caner, Talat Aykut, Mehmet Artaç, Mustafa Emre Duygulu, Nadiye Sever, Sıla Öksüz, Nedim Turan, Musa Barış Aykan, Esmanur Kaplan Tüzün, Mükremin Uysal, İrem Uğurlu, Abdullah Sakin, Caner Acar, Duygu Özaşkın, Teoman Şakalar, Merve Keskinkılıç, Tuğba Yavuzşen, Naziyet Köse, İsmail Ertürk, Nilgün Yıldırım, Onur Yazdan Balçık, Ali Alkan, Oğuzhan Selvi, Eda Erçin, Olçun Ümit Ünal, Cengiz Karaçin
{"title":"Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study.","authors":"İsmail Beypınar, Hacer Demir, Şendağ Yaslıkaya, Tolga Köşeci, Bilgin Demir, Gökhan Çolak, Ahmet Burak Ağaoğlu, Mustafa Şahbazlar, Pervin Can Şancı, Devrim Çabuk, Ulaş Işık, Elif Şahin, Alper Coşkun, Burcu Caner, Talat Aykut, Mehmet Artaç, Mustafa Emre Duygulu, Nadiye Sever, Sıla Öksüz, Nedim Turan, Musa Barış Aykan, Esmanur Kaplan Tüzün, Mükremin Uysal, İrem Uğurlu, Abdullah Sakin, Caner Acar, Duygu Özaşkın, Teoman Şakalar, Merve Keskinkılıç, Tuğba Yavuzşen, Naziyet Köse, İsmail Ertürk, Nilgün Yıldırım, Onur Yazdan Balçık, Ali Alkan, Oğuzhan Selvi, Eda Erçin, Olçun Ümit Ünal, Cengiz Karaçin","doi":"10.1007/s10549-024-07456-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences.</p><p><strong>Method: </strong>The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series.</p><p><strong>Results: </strong>One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival.</p><p><strong>Conclusion: </strong>This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"597-604"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-024-07456-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences.
Method: The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series.
Results: One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival.
Conclusion: This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment.
期刊介绍:
Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.